Fuzionaire Diagnostics and McMaster University in Hamilton, Ontario, Canada, have signed a collaborative research agreement to develop theranostic radiopharmaceuticals.
The radiopharmaceutical will be developed using Fuzionaire Dx's HetSiFA (heteroaromatic silicon-fluoride acceptors) platform and will be evaluated at McMaster's preclinical nuclear medicine facilities, according to the firm.
Fuzionaire's HetSiFA platform is compatible with fluorine-18 (F-18), which is used for PET imaging.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
